GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » Market Cap

RVL Pharmaceuticals (RVL Pharmaceuticals) Market Cap : $0.06 Mil (As of May. 18, 2024)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). RVL Pharmaceuticals's share price for the quarter that ended in Jun. 2023 was $0.5601. RVL Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 99.39 Mil. Therefore, RVL Pharmaceuticals's market cap for the quarter that ended in Jun. 2023 was $55.67 Mil.

RVL Pharmaceuticals's quarterly market cap increased from Dec. 2022 ($111.06 Mil) to Mar. 2023 ($113.26 Mil) but then declined from Mar. 2023 ($113.26 Mil) to Jun. 2023 ($55.67 Mil).

RVL Pharmaceuticals's annual market cap declined from Dec. 2020 ($257.69 Mil) to Dec. 2021 ($89.96 Mil) but then increased from Dec. 2021 ($89.96 Mil) to Dec. 2022 ($111.06 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. RVL Pharmaceuticals's Enterprise Value for Today is $39.04 Mil.


RVL Pharmaceuticals Market Cap Historical Data

The historical data trend for RVL Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Market Cap Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial 407.02 362.40 257.69 89.96 111.06

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.72 208.22 111.06 113.26 55.67

Competitive Comparison of RVL Pharmaceuticals's Market Cap

For the Biotechnology subindustry, RVL Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Market Cap falls into.



RVL Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

RVL Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$1.12*99.1614
=$111.06

RVL Pharmaceuticals's Market Cap for the quarter that ended in Jun. 2023 is calculated as

Market Cap (Q: Jun. 2023 )=Share Price (Q: Jun. 2023 )*Shares Outstanding (EOP) (Q: Jun. 2023 )
=$0.5601*99.3922
=$55.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RVL Pharmaceuticals  (OTCPK:RVLPQ) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


RVL Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
Executives
Foundation Harsaul 10 percent owner EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd 10 percent owner KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p. 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison director, officer: Chief Executive Officer 501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman director, 10 percent owner C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell 10 percent owner ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub officer: EVP and COO 400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807